Outlook Therapeutics (OTLK) Work In Process (2025 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Work In Process of $797880.0 for Q1 2026, up 194.21% year-over-year from $271190.0 in Q1 2025, and down 27.98% quarter-over-quarter from $1.1 million in Q4 2025.
Outlook Therapeutics (OTLK) Work In Process (2025 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Work In Process for 2 consecutive years, with $797880.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Work In Process rose 194.21% year-over-year to $797880.0; the TTM figure through Mar 2026 stood at $797880.0 (up 194.21% YoY), while the FY2025 annual figure was $958539.0, changed N/A from the prior year.
- Work In Process eased to $797880.0 in Q1 2026 per OTLK's latest filing, from $1.1 million in the prior quarter.
- Across five years, Work In Process topped out at $3.7 million in Q2 2025 and bottomed at $271190.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Outlook Therapeutics | 93.64 Mn | 82.40 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 797,880.00 |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 958,539.00 |
| Jun 30, 2025 | 3.75 Mn |
| Mar 31, 2025 | 271,190.00 |